Veterinary Medicines

Doxycare Flavour 200 mg Tablets for Cats and Dogs

Authorised
  • Doxycycline hyclate
Download as PDF

Product identification

Medicine name:
Doxycare Flavour 200 mg Tablets for Cats and Dogs
Doxycare 200 mg Tablet
Doxycare 200 mg Comprimé
Doxycare 200 mg Tablette
Active substance:
  • Doxycycline hyclate
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Doxycycline hyclate
    239.40
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01AA02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 90 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 100 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 250 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 10 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 20 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 30 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 40 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 50 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 60 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 70 tablets.
  • OPA/Aluminium/PVC foil and Aluminium foil blister containing 10 tabletsCardboard box of 80 tablets.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ecuphar
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lely Pharma B.V.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V552133
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0645/002
Concerned member states:
  • Austria
  • Belgium
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 13/04/2025
Download
Dutch (PDF)
Published on: 16/10/2025
Download
French (PDF)
Published on: 16/10/2025
Download
German (PDF)
Published on: 16/10/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 16/10/2025
Download
French (PDF)
Published on: 16/10/2025
Download
German (PDF)
Published on: 16/10/2025
Download

Combined File of all Documents

English (PDF)
Published on: 6/04/2025
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 16/10/2025
Download
French (PDF)
Published on: 16/10/2025
Download
German (PDF)
Published on: 16/10/2025
Download